Margrit Schwarz

Margrit Schwarz has extensive experience in various leadership and expert roles within the biotechnology and innovation sectors. Margrit currently serves as a Board Director at Altamira Therapeutics, an Entrepreneur in Residence at BiOrigin, Novo Seeds, and an Expert at Innosuisse - Swiss Innovation Agency.

In the past, Margrit has held positions as an Expert, Startup Coach, and EIC Jury Member at the European Innovation Council and SMEs Executive Agency (EISMEA). Margrit has also served as a Board Member and VP Industry at KERN LIPID CONFERENCE.

Margrit has co-founded and served as CEO of BlackWay Biosciences AG. Margrit has held the position of Chief Business Officer at HepaRegeniX GmbH from February 2022 to January 2023. Prior to that, they were the Chief Operating Officer at Draupnir Bio from March 2020 to February 2022.

Margrit's experience also includes being the Chief Scientific Officer and Head of R&D at Genevant Sciences from January 2019 to March 2020, and serving as the Vice President and Global Head of External Innovation in Therapeutic Modalities at Roche from December 2016 to December 2018.

Margrit Schwarz's education history is as follows:

From 1984 to 1990, Margrit Schwarz attended the University of Münster, where they obtained a Diploma in Chemistry.

Subsequently, from 1990 to 1994, Margrit Schwarz pursued their Ph.D. in Biochemistry at the University of Cologne.

Later, from 2009 to 2010, Margrit Schwarz completed an MBA program at Columbia Business School. During this same period, they also obtained another MBA degree in Business from the University of California, Berkeley, Haas School of Business.